EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Urinary rituximab loss and rate of treatment failure in membranous nephropathy

Marco Allinovi iD, Matteo Accinno, Cecilia Finocchi, Tommaso Mazzierli, Leonardo Caroti, Daniela Lazzarini, Lorenzo Cosmi, Andrea Matucci, Marco Del Carria iD, Michael Diomaiuti, Calogero Lino Cirami, Francesco Peyronel iD und 1 weitere

Nephrology Dialysis Transplantation · 23.12.2025 · 41 (1) · 92-101

DOI: 10.1093/ndt/gfaf127 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 07.07.2025. Verfasst von Marco Allinovi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology, Dialysis and Transplantation Unit, Careggi University Hospital, Florence, Italy. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Rituximab, Proteinuria, Immunologic Factors. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rituximab is a first-line treatment for primary membranous nephropathy, but approximately one-third of patients fail to respond. Among the proposed mechanisms of rituximab resistance, urinary rituximab loss due to non-selective proteinuria could lead to drug underexposure and treatment failure. Although hypothesized, this has never been objectively measured with a practical and reproducible method.

Methods

We conducted a prospective, observational study of 25 patients with biopsy-proven primary membranous nephropathy treated with rituximab (two infusions of 1 g, 2 weeks apart) at Careggi University Hospital, Florence, Italy. Rituximab levels were measured in serum and urine using a commercially available ELISA adapted for urinary samples. Urinary rituximab concentrations were assessed in 60 individuals to identify a threshold below which rituximab is considered not present in urine. Eight non-responders with urinary rituximab ≥2 µg/ml (potentially underexposed) received a second treatment course to test whether a higher rituximab dose would provide benefits in terms of kidney outcomes.

Results

Urinary rituximab loss was associated with markers of disease severity, including lower eGFR (r = −0.50; P = .01), higher proteinuria (r = 0.46; P = .02), and non-selective proteinuria (r = 0.61; P = .001). Patients with urinary rituximab ≥2 µg/ml had lower serum rituximab peak levels at 1 month (P = .04), possibly reflecting drug underexposure, and significantly lower response rates (43% vs 100%, P = .003). Phospholipase A2 receptor antibody depletion was significantly more frequent in patients with lower urinary rituximab levels (80% vs 17%, P = .008). In the re-treated subgroup, five of eight non-responders showing significant urinary rituximab loss and receiving a second course of treatment achieved clinical response.

Conclusions

In primary membranous nephropathy, urinary rituximab loss is associated with disease severity, drug underexposure, and treatment failure. Measuring urinary rituximab could help identify patients at risk of resistance who could benefit from additional rituximab dosing. This approach could improve outcome prediction and support personalized immunosuppressive strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, MembranousRituximabProteinuriaImmunologic FactorsHumansFemaleProspective StudiesMaleMiddle AgedAdultTreatment FailurePrognosisFollow-Up StudiesGlomerular Filtration RateAged

Stichwörter der Autor:innen

membranous nephropathynon-selective proteinuriarituximabrituximab resistanceurinary rituximab loss

Substanzen

RituximabImmunologic Factors

Autor:innen und Institutionen

  • Nephrology, Dialysis and Transplantation Unit, Careggi University Hospital, Florence, Italy.
  • Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
  • Immunoallergology Unit, Careggi University Hospital, Florence, Italy.

ORCID-Profile: Marco Allinovi, Marco Del Carria, Francesco Peyronel

Zitieren

APA

Allinovi, M., Accinno, M., Finocchi, C., Mazzierli, T., Caroti, L., Lazzarini, D., Cosmi, L., Matucci, A., Del Carria, M., Diomaiuti, M., Cirami, C. L., Peyronel, F., & Vultaggio, A. (2025). Urinary rituximab loss and rate of treatment failure in membranous nephropathy. Nephrology Dialysis Transplantation, 41(1), 92-101. https://doi.org/10.1093/ndt/gfaf127

Vancouver

Allinovi M, Accinno M, Finocchi C, Mazzierli T, Caroti L, Lazzarini D, et al. Urinary rituximab loss and rate of treatment failure in membranous nephropathy. Nephrology Dialysis Transplantation. 2025;41(1):92-101. doi:10.1093/ndt/gfaf127

BibTeX
@article{Allinovi2025,
  author = {Allinovi, Marco and Accinno, Matteo and Finocchi, Cecilia and Mazzierli, Tommaso and Caroti, Leonardo and Lazzarini, Daniela and Cosmi, Lorenzo and Matucci, Andrea and Del Carria, Marco and Diomaiuti, Michael and Cirami, Calogero Lino and Peyronel, Francesco and Vultaggio, Alessandra},
  title = {Urinary rituximab loss and rate of treatment failure in membranous nephropathy},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  volume = {41},
  number = {1},
  pages = {92--101},
  doi = {10.1093/ndt/gfaf127}
}
Kostenlos starten →